MX2007007103A - Derivados espiro como inhibidores de lipoxigenasa. - Google Patents
Derivados espiro como inhibidores de lipoxigenasa.Info
- Publication number
- MX2007007103A MX2007007103A MX2007007103A MX2007007103A MX2007007103A MX 2007007103 A MX2007007103 A MX 2007007103A MX 2007007103 A MX2007007103 A MX 2007007103A MX 2007007103 A MX2007007103 A MX 2007007103A MX 2007007103 A MX2007007103 A MX 2007007103A
- Authority
- MX
- Mexico
- Prior art keywords
- lipoxygenase inhibitors
- lipoxygenase
- spiro derivatives
- manufacture
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La presente invencion se refiere a ciertos derivados de anillo heterociclico espiro-substituidos novedosos. Esto compuestos pueden ser utiles en la elaboracion de composiciones farmaceuticas para tratar trastornos mediados por lipoxigenasa. Tambien pueden ser utiles en la elaboracion de formulaciones farmaceuticas para el tratamiento de trastornos mediados por lipoxigenasa.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63558104P | 2004-12-13 | 2004-12-13 | |
US65670905P | 2005-02-25 | 2005-02-25 | |
US65671005P | 2005-02-25 | 2005-02-25 | |
US67538605P | 2005-04-27 | 2005-04-27 | |
US70258005P | 2005-07-26 | 2005-07-26 | |
PCT/US2005/044768 WO2006065686A2 (en) | 2004-12-13 | 2005-12-09 | Spiro derivatives as lipoxygenase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007007103A true MX2007007103A (es) | 2008-03-10 |
Family
ID=36370831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007007103A MX2007007103A (es) | 2004-12-13 | 2005-12-09 | Derivados espiro como inhibidores de lipoxigenasa. |
Country Status (8)
Country | Link |
---|---|
US (1) | US7576094B2 (es) |
EP (1) | EP1836183A2 (es) |
JP (1) | JP2008523145A (es) |
AU (1) | AU2005316739A1 (es) |
BR (1) | BRPI0519013A2 (es) |
CA (1) | CA2589363A1 (es) |
MX (1) | MX2007007103A (es) |
WO (1) | WO2006065686A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
CA2599352A1 (en) * | 2005-02-25 | 2006-09-08 | Eli Lilly And Company | Novel lipoxygenase inhibitors |
MX2007010328A (es) * | 2005-02-25 | 2008-03-13 | Lilly Co Eli | Cromanos, tiocromanos y dihidroquinolinas espiro-heterociclicos. |
NZ571706A (en) * | 2006-04-18 | 2012-06-29 | Abbott Lab | Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof |
CA2669884A1 (en) * | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
US7939690B2 (en) * | 2006-11-15 | 2011-05-10 | High Point Pharmaceuticals, Llc | Haloalkylsulfone substituted compounds useful for treating obesity and diabetes |
CA2669874A1 (en) * | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
WO2008059024A1 (en) * | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
GEP20125707B (en) * | 2007-12-18 | 2012-12-10 | Glenmark Pharmaceuticals Sa | Chromane derivatives as trpv3 modulators |
CA2724008A1 (en) | 2008-01-11 | 2009-09-11 | Prasada Rao V.S. Lingam | Fused pyrimidine derivatives as trpv3 modulators |
CA2728405A1 (en) * | 2008-06-17 | 2010-01-14 | Glenmark Pharmaceuticals, S.A. | Chromane derivatives as trpv3 modulators |
US8318928B2 (en) | 2008-12-15 | 2012-11-27 | Glenmark Pharmaceuticals, S.A. | Fused imidazole carboxamides as TRPV3 modulators |
US8344010B2 (en) | 2008-12-26 | 2013-01-01 | Glenmark Pharmaceuticals S.A. | Fused imidazole derivatives as TRPV3 antagonist |
WO2015027146A1 (en) | 2013-08-22 | 2015-02-26 | The General Hospital Corporation | Inhibitors of human 12/15-lipoxygenase |
KR102153772B1 (ko) | 2013-09-09 | 2020-09-09 | 펠로톤 테라퓨틱스, 인크. | 아릴 에테르 및 이의 용도 |
US9884843B2 (en) | 2013-12-16 | 2018-02-06 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
US9796680B2 (en) * | 2013-12-23 | 2017-10-24 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
WO2016145045A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating glioblastoma |
US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
WO2016144826A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
US10278942B2 (en) | 2015-03-11 | 2019-05-07 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
WO2016168510A1 (en) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
WO2017087795A1 (en) | 2015-11-19 | 2017-05-26 | Concert Pharmaceuticals, Inc. | Deuterated epi-743 |
US20230203035A1 (en) * | 2021-12-23 | 2023-06-29 | The Katholieke Universiteit Leuven | Spiros and Related Analogs for Inhibiting YAP/TAZ-TEAD |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3331846A (en) | 1963-08-28 | 1967-07-18 | Lilly Co Eli | Metal catalyst process for converting alpha-amino-acetylenes to dihydroquinoline |
US3574627A (en) | 1969-02-06 | 1971-04-13 | Eastman Kodak Co | Color photographic elements |
JPS5265267A (en) | 1975-11-26 | 1977-05-30 | Takeda Chem Ind Ltd | Synthesis of spiro compounds |
JPS6030671B2 (ja) | 1976-12-13 | 1985-07-17 | 武田薬品工業株式会社 | スピロ化合物 |
US4284644A (en) | 1977-01-12 | 1981-08-18 | Takeda Chemical Industries, Ltd. | Spirobenzofuranone compounds |
US4342779A (en) | 1977-12-27 | 1982-08-03 | Takeda Chemical Industries, Ltd. | 7-Acetylspirobenzofuranone compound |
HU179601B (en) | 1977-12-27 | 1982-11-29 | Takeda Chemical Industries Ltd | Process for producing spirobenzofuranone derivatives |
JPS5646879A (en) | 1979-09-25 | 1981-04-28 | Takeda Chem Ind Ltd | Spiro compound, its preparation, and preventive and remedy for circulatory system disorder |
US4330554A (en) | 1980-04-23 | 1982-05-18 | Takeda Chemical Industries, Ltd. | Spirobenzofuranone compounds |
FI79535C (fi) | 1982-05-06 | 1990-01-10 | Erba Farmitalia | Foerfarande foer framstaellning av dihydrobensopyrans och dihydrobensotiopyrans substituerade iminoderivat. |
EP0095316B1 (en) | 1982-05-21 | 1986-12-03 | Beecham Group Plc | Pharmaceutically active aminobenzopyrans |
DE3479726D1 (de) | 1983-05-18 | 1989-10-19 | Beecham Group Plc | Benzopyran derivatives. |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4761403A (en) | 1986-04-09 | 1988-08-02 | Abbott Laboratories | Lipoxygenase inhibiting compounds |
AU7875487A (en) | 1986-08-08 | 1988-02-24 | Upjohn Company, The | Methods, compositions and solutions for treating alopecia |
GB8625185D0 (en) | 1986-10-21 | 1986-11-26 | Beecham Group Plc | Active compounds |
GB8626344D0 (en) | 1986-11-04 | 1986-12-03 | Zyma Sa | Bicyclic compounds |
US5387587A (en) | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
EP0273647B1 (en) | 1986-12-27 | 1992-03-11 | Takeda Chemical Industries, Ltd. | Coumaran derivatives, their production and use |
GB8701022D0 (en) | 1987-01-19 | 1987-02-18 | Beecham Group Plc | Treatment |
GB8723157D0 (en) | 1987-10-02 | 1987-11-04 | Beecham Group Plc | Compounds |
US5059609A (en) | 1987-10-19 | 1991-10-22 | Pfizer Inc. | Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases |
GB8800199D0 (en) | 1988-01-06 | 1988-02-10 | Beecham Group Plc | Pharmaceutical preparation |
JPH07121936B2 (ja) | 1988-03-28 | 1995-12-25 | キッセイ薬品工業株式会社 | ジヒドロベンゾフラノン誘導体 |
US5021432A (en) | 1988-04-26 | 1991-06-04 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzopyran compound and its pharmaceutical use |
AU628331B2 (en) | 1988-05-06 | 1992-09-17 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
US4950684A (en) | 1988-05-20 | 1990-08-21 | G. D. Searle & Co. | 2,2-di-substituted benzopyran leukotriene-D4 antagonists |
US5015661A (en) | 1988-08-09 | 1991-05-14 | Hoffmann-La Roche Inc. | Chromanes and their pharmaceutical compositions and methods |
GB8902118D0 (en) | 1989-02-01 | 1989-03-22 | Beecham Group Plc | Chemical process |
US5232938A (en) | 1989-05-24 | 1993-08-03 | Beecham Group P.L.C. | Certain 1,2,4-triazole(oxy or amino)benzopyran derivatives having pharmacological activity |
DE3918041A1 (de) | 1989-06-02 | 1990-12-06 | Merck Patent Gmbh | Chromanderivate |
GB8915315D0 (en) | 1989-07-04 | 1989-08-23 | Sandoz Ltd | Pharmaceutical compositions for use against hypertension and congestive heart failure |
US5350747A (en) | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
JPH0366669A (ja) | 1989-08-03 | 1991-03-22 | Shionogi & Co Ltd | 複素環式化合物 |
GB8924373D0 (en) | 1989-10-30 | 1989-12-20 | Beecham Group Plc | Novel compounds |
GB2242628A (en) | 1990-04-06 | 1991-10-09 | Sandoz Ltd | Asthma prophylactic use of K+ channel activators |
BE1004295A3 (fr) | 1990-05-17 | 1992-10-27 | Sandoz Sa | Utilisation des activateurs des canaux potassiques pour la prophylaxie de l'asthme. |
US5076835A (en) | 1990-05-31 | 1991-12-31 | America Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
DE4018552A1 (de) | 1990-06-09 | 1991-12-12 | Sandoz Ag | Asthma-prophylaktische verwendung von k(pfeil hoch)+(pfeil hoch) kanal-activatoren |
ES2030627A6 (es) | 1990-11-28 | 1992-11-01 | Uriach & Cia Sa J | Procedimiento para la obtencion de compuestos benzopiranicos. |
JP2612971B2 (ja) | 1991-02-19 | 1997-05-21 | 吉富製薬株式会社 | ベンゾピラン化合物 |
DE4115521A1 (de) | 1991-05-11 | 1992-11-12 | Beiersdorf Ag | Isoindolyl- und isochinolylsubstituierte benzopyran-derivate, zwischenprodukte, sowie verfahren zu ihrer herstellung |
US5624954A (en) | 1991-06-13 | 1997-04-29 | Smithkline Beecham P.L.C. | Benzo- and pyridopyran derivatives having anxiolytic and anti-convulsant activity |
US5250547A (en) | 1991-08-29 | 1993-10-05 | Syntex (U.S.A.) Inc. | Benzopyran derivatives |
CA2053962A1 (en) | 1991-10-22 | 1993-04-23 | Theo Schotten | Benzopyran derivatives, process for their preparation and use thereof and preparations containing the compounds |
CA2124086A1 (en) | 1991-11-22 | 1993-05-27 | Ronald H. Lane | Tocotrienols and tocotrienol-like compounds and methods for their use |
FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
AU661159B2 (en) | 1992-07-15 | 1995-07-13 | Sumitomo Chemical Company, Limited | N-acyldihydroquinoline derivatives, a method for producing the same and their use as herbicides |
FR2695387B1 (fr) | 1992-09-09 | 1994-10-21 | Adir | Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
EP0662962A1 (en) | 1992-09-28 | 1995-07-19 | Pfizer Inc. | Substituted pyrimidines for control of diabetic complications |
US5939346A (en) | 1992-11-02 | 1999-08-17 | Akzo Nobel N.V. | Catalyst system comprising an aryloxyaluminoxane containing an electron withdrawing group |
KR100326968B1 (ko) | 1992-12-11 | 2002-07-27 | 스미스클라인비이참피이엘시이 | 약학적 활성을 가진 이환식 화합물 |
DE69327965T2 (de) | 1992-12-11 | 2000-10-19 | Smithkline Beecham Plc | Pharmazeutische zusammenstellung enthaltende bizyklisch typ verbindungen |
FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5399562A (en) | 1994-02-04 | 1995-03-21 | G. D. Searle & Co. | Indolones useful as serotonergic agents |
TW279878B (es) | 1994-03-18 | 1996-07-01 | Sumitomo Chemical Co | |
JP3528242B2 (ja) | 1994-06-23 | 2004-05-17 | 住友化学工業株式会社 | ヒドロキシフラバン化合物の製造方法 |
DE4428932A1 (de) | 1994-08-16 | 1996-02-22 | Hoechst Ag | Substituierte-Chinolinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
EP0700959A1 (en) | 1994-09-07 | 1996-03-13 | Sumitomo Chemical Company, Limited | A rubber composition and a vulcanizing adhesion method using the same |
CA2202056A1 (en) | 1994-10-13 | 1996-04-25 | Mark A. Dombroski | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists |
AU696890B2 (en) | 1994-10-13 | 1998-09-24 | Pfizer Inc. | Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists |
US5688808A (en) | 1994-12-22 | 1997-11-18 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
US5925673A (en) | 1994-12-23 | 1999-07-20 | Alcon Laboratories, Inc. | Benzofurans and benzopyrans as cytoprotective agents |
US5674876A (en) | 1995-01-20 | 1997-10-07 | Research Development Foundation | ρ-heteroatom-substituted phenols and uses thereof |
FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
US5606006A (en) | 1996-04-08 | 1997-02-25 | Shell Oil Company | Trisepoxy resin compositions |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
US6005007A (en) | 1997-07-18 | 1999-12-21 | Farmer; Luc J. | Retinoids, methods for their production and use |
FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE19854147A1 (de) | 1998-11-24 | 2000-05-25 | Basf Ag | Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht |
FR2787451B1 (fr) | 1998-12-18 | 2001-01-26 | Adir | Nouveaux composes imidazoliniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2787789B1 (fr) | 1998-12-29 | 2002-06-14 | Lipha | Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations |
DE10007948A1 (de) | 2000-02-22 | 2001-09-06 | Wella Ag | Mittel zur Färbung von Fasern |
US20030212109A1 (en) | 2000-06-02 | 2003-11-13 | Mitchell Stephen Nicholas | Pharmaceutical compositions and their use |
MXPA03000952A (es) | 2000-08-01 | 2003-09-05 | Ono Pharmaceutical Co | Compuestos derivados de 3,4-dihidroisoquinolina y medicamentos que los contienen, como el ingrediente activo. |
US6291677B1 (en) | 2000-08-29 | 2001-09-18 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6313107B1 (en) | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
US6369225B1 (en) | 2000-08-29 | 2002-04-09 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6252090B1 (en) | 2000-08-29 | 2001-06-26 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US7205407B2 (en) | 2001-11-20 | 2007-04-17 | Eli Lilly And Company | 3-Substituted oxindole β3 agonists |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US7205328B2 (en) | 2002-10-21 | 2007-04-17 | Irm Llc | Oxindoles with anti-HIV activity |
CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
EP1708713B1 (en) | 2004-01-16 | 2008-03-12 | F. Hoffmann-la Roche AG | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d)(1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
US20060106014A1 (en) | 2004-10-14 | 2006-05-18 | Sekhar Boddupalli | Methods for treating diabetes |
CA2599352A1 (en) | 2005-02-25 | 2006-09-08 | Eli Lilly And Company | Novel lipoxygenase inhibitors |
-
2005
- 2005-12-09 CA CA002589363A patent/CA2589363A1/en not_active Abandoned
- 2005-12-09 EP EP05853636A patent/EP1836183A2/en not_active Withdrawn
- 2005-12-09 AU AU2005316739A patent/AU2005316739A1/en not_active Abandoned
- 2005-12-09 MX MX2007007103A patent/MX2007007103A/es not_active Application Discontinuation
- 2005-12-09 WO PCT/US2005/044768 patent/WO2006065686A2/en active Application Filing
- 2005-12-09 BR BRPI0519013-4A patent/BRPI0519013A2/pt not_active IP Right Cessation
- 2005-12-09 US US11/298,137 patent/US7576094B2/en not_active Expired - Fee Related
- 2005-12-09 JP JP2007546793A patent/JP2008523145A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2589363A1 (en) | 2006-06-22 |
US7576094B2 (en) | 2009-08-18 |
EP1836183A2 (en) | 2007-09-26 |
WO2006065686A2 (en) | 2006-06-22 |
JP2008523145A (ja) | 2008-07-03 |
AU2005316739A1 (en) | 2006-06-22 |
US20060128790A1 (en) | 2006-06-15 |
WO2006065686A3 (en) | 2006-08-24 |
BRPI0519013A2 (pt) | 2009-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007007103A (es) | Derivados espiro como inhibidores de lipoxigenasa. | |
MX2009006543A (es) | Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer. | |
MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
MY159615A (en) | Fused heterocyclic derivatives and methods of use as c-met inhibitors | |
MX2009002657A (es) | Derivados dibenzofurano como inhibidores de pde-4 y pde-10. | |
TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
WO2008121861A3 (en) | Pyrazole and pyrrole compounds useful in treating iron disorders | |
MX2009006706A (es) | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
TW200745004A (en) | Novel compounds, their preparation and use | |
TW200716596A (en) | Substituted amide derivatives and methods of use | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NZ596579A (en) | Bace inhibitors | |
UA99882C2 (uk) | Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти) | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
EA201290255A1 (ru) | Способы и композиции для лечения рака | |
WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
NO20090979L (no) | (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater | |
MX2009003763A (es) | Inhibidores de metaloproteasa derivados de heterociclicos. | |
GEP20135806B (en) | Lactams as beta secretase inhibitors | |
EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
ATE368666T1 (de) | Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren | |
ATE388708T1 (de) | Piperazinderivate und anwendungsverfahren | |
EA200702030A1 (ru) | Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз | |
DE602004005960D1 (de) | Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |